Akcea Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$668.2M
Industry:Biotech
Founded:2015
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Akcea Therapeutics's estimated annual revenue is currently $64.9M per year.
  • Akcea Therapeutics's estimated revenue per employee is $188,567
  • Akcea Therapeutics's total funding is $668.2M.

Employee Data

  • Akcea Therapeutics has 344 Employees.
  • Akcea Therapeutics grew their employee count by 46% last year.
  • Akcea Therapeutics currently has 19 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea () is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence. http://www.fiercebiotech.com/story/isis-launches-cardio-subsidiary-and-recruits-genzyme-vet-run-it/2015-01-07

keywords:N/A

344

Number of Employees

$64.9M

Revenue (est)

19

Current Jobs

46%

Employee Growth %

$668.2M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Ken BushRegional Case Manager
Kari HansonManager, Rare Disease
Nancy JohansenDirector Global Regulatory AffairsEmail Available
Victoria BartlettDirector Of Alliance And Program Management
Victoria DrizinManager, OS & Sr. Exec. Assistant
Paul SchmidtHead of Financial Planning & Analysis
Todd AmrheinAssociate Director, Global Training, Learning, & DevelopmentEmail Available
Christine GoldsberryRegional Account Manager
Dan MoynihanChief Compliance OfficerEmail Available
Rebecca ArcherNurse Case ManagerEmail Available

Akcea Therapeutics News

09/03/2019 - Akcea Therapeutics And AKCEA-ANGPTL3-LRx: The Story

Liver Therapy Forum weekly digest provides an overview on what's happening in liver diseases in 2019. This week's spotlight is Akcea ...

09/08/2019 - Here's Why Akcea Therapeutics, Inc. (AKCA) Dropped -1.5%

In its most recent trading session, Akcea Therapeutics, Inc. (AKCA) dropped by -1.5% – here is what that looked like (as of 2019-08-23): ...

09/03/2019 - Akcea Therapeutics Inc (NASDAQ:AKCA) Receives Average Rating of “Hold” from Analysts

Akcea Therapeutics Inc (NASDAQ:AKCA) has received an average recommendation of “Hold” from the eight ratings firms that are currently ...

Akcea Therapeutics Executive Hires

DateNameTitleReference
2016-01-20Louis St. L. O'DeaChief Medical OfficerArticle
2017-10-05Nelly KomariMedical DirectorArticle